Atea Pharmaceuticals Inc (NASDAQ: AVIR) — Perfil da empresa, notícias e dados financeiros
Atea Pharmaceuticals focuses on antiviral therapeutics for serious viral infections like COVID-19 and hepatitis C.
Atea Pharmaceuticals Inc
Atea Pharmaceuticals (NASDAQ:AVIR) is a biopharmaceutical company focused on the discovery, development, and commercialization of antiviral therapeutics for serious viral infections. Their portfolio is primarily geared towards addressing unmet medical needs in diseases caused by the hepatitis C virus, dengue, respiratory syncytial virus, and COVID-19 among others. With a strong emphasis on innovation, Atea is dedicated to pushing the boundaries of science to create effective treatments that can significantly improve patients' lives. Their objectives include advancing their current drug candidates through clinical trials, expanding their research into new antiviral targets, and forging strategic partnerships to enhance their reach and impact in the global healthcare market.
Resumo
Operações
Produtos e/ou serviços de Atea Pharmaceuticals Inc
- Ruzasvir, a single tablet regimen for chronic hepatitis C virus, focusing on genotype 1 patients.
- Bemnifosbuvir, an oral polymerase inhibitor for the treatment of COVID-19.
- Development of Bemnifosbuvir in combination therapies for enhanced efficacy against COVID-19 and other viral infections.
- Pipeline of nucleotide analogs targeting unmet needs in viral diseases, including respiratory syncytial virus (RSV).
- Research collaborations to explore new antiviral compounds for emerging infectious diseases.
equipe executiva do Atea Pharmaceuticals Inc
- Jean-Pierre SommadossiFounder, Chairman, CEO & President
- Andrea J. CorcoranCFO, Executive VP of Legal & Secretary
- John F. VavrickaChief Commercial Officer
- Janet M. J. HammondChief Development Officer
- Maria Arantxa HorgaChief Medical Officer
- Wayne FosterExecutive VP of Finance & Chief Accounting Officer
- Jonae R. BarnesSenior Vice President of Investor Relations & Corporate Communications
- Adel MoussaExecutive Vice President of Chemistry
- Xiao-Jian ZhouExecutive Vice President of Early Stage Development
- Keith PietropaoloExecutive VP of Clinical Sciences & Project Management
Principais indicadores financeiros
Resultados divulgados pela Atea Pharmaceuticals Inc, em USD.
- Cap. de mercado
- 342,5 mi
- Receita (TTM)
- 192,2 mi
- P/L
- —
- LPA (diluído, TTM)
- -2.1
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -180,9 mi | -158,3 mi | |
| 0 | -193 mi | -168,4 mi | |
| 0 | -164,2 mi | -136 mi | |
| 192,2 mi | -130,7 mi | -115,9 mi |